These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 21851507

  • 21. DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype.
    Seary ME, Feldman D, Carcao MD.
    Haemophilia; 2012 Jan; 18(1):50-5. PubMed ID: 21592259
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A.
    Chaves D, Belisário A, Castro G, Santoro M, Rodrigues C.
    Int J Immunogenet; 2010 Apr; 37(2):79-82. PubMed ID: 20082647
    [Abstract] [Full Text] [Related]

  • 24. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A, Kavakli K, Baytan B, Kazanci E, Sayli T, Oren H, Celkan T, Gursel T.
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
    Madoiwa S, Kobayashi E, Kashiwakura Y, Sakata A, Yasumoto A, Ohmori T, Mimuro J, Sakata Y.
    Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J, Berntorp E, Lindvall K, Björkman S.
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
    Ter Avest PC, Fischer K, Gouw SC, Van Dijk K, Mauser-Bunschoten EP.
    Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM.
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [Abstract] [Full Text] [Related]

  • 35. Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone.
    Holstein K, Marx G, Lentz B, Bokemeyer C, Langer F.
    Hamostaseologie; 2012 Mar; 32 Suppl 1():S48-51. PubMed ID: 22960877
    [Abstract] [Full Text] [Related]

  • 36. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients.
    Pinto P, Ghosh K, Shetty S.
    Haemophilia; 2012 Sep; 18(5):794-7. PubMed ID: 22630053
    [Abstract] [Full Text] [Related]

  • 37. Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A.
    Aznar JA, Moret A, Ibáñez F, Vila C, Cabrera N, Mesa E, Bonanad S.
    Haemophilia; 2014 Sep; 20(5):624-9. PubMed ID: 24697977
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.